Hypotension or excessive blood pressure reduction must be avoided in patients with compromised cerebral or cardiac circulation.
Fluid retention from prolonged therapy may compromise the condition of patients with congestive heart failure.
Hyperglycemia may occur, particularly in patients with diabetes or hepatic dysfunction.
Parenteral product is highly alkaline and intended only for IV administration.
Use in pregnancy. FDA Category C (indeterminate). This drug has caused skeletal, cardiac, and pancreatic abnormalities in animals, but no adequate human data exist. Use of this drug near term may cause hyperbilirubinemia and altered carbohydrate metabolism in a fetus or neonate, and intravenous administration during labor may cause cessation of uterine contractions. These cautions, however, do not necessarily preclude acute, short-term use of the drug for a seriously symptomatic patient (See Introduction in Section III).